AzTrials
AzTrials

Agitation in Participants With Dementia of the Alzheimer's TypePhase 3NCT02442778

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

A Phase 3 study testing AVP-786-18, AVP-786-28 and AVP-786-42.63 in people with Agitation in Participants With Dementia of the Alzheimer's Type, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 83 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups. Read more about this study

Who is it for?
Ages 50 to 90 years
What is being tested?
AVP-786-18, AVP-786-28 and AVP-786-42.63
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
522 participants
Where
83 sitesin 2 countries
Study dates
11 Nov 2015to 9 Sep 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of probable Alzheimer's Disease (AD) according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
  • The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
  • The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation
  • Either out participants or residents of an assisted-living facility or a skilled nursing home
  • Clinical Global Impression of Severity of Illness (CGIS) score assessing Agitation is >=4 (moderately ill) at screening and baseline
  • Mini-Mental State Examination (MMSE) score is between 6 and 26 (inclusive) at screening and baseline
  • Caregiver who is able and willing to comply with all required study procedures. In order to qualify as a reliable informant (i.e., caregiver) capable of assessing changes in participant's condition during the study, the individual must spend a minimum of 2 hours per day for 4 days per week with the participant.

Who cannot join

  • Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
  • Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
  • Participant with myasthenia gravis

Trial locations and contacts

83 sites in 2 countries.

83 sites in 2 countries

United States79 sites
  • Daystar Clinical Research Inc

    Akron, Ohio, 44313

  • Emory Brain Health Center

    Atlanta, Georgia, 30329

  • JEM Research Institute

    Atlantis, Florida, 33462

  • Heritage Valley Medical Group, Inc.

    Beaver, Pennsylvania, 15009

  • Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic

    Bennington, Vermont, 05201

  • Clinical Research Of Brandon, LLC

    Brandon, Florida, 33511

  • Brooklyn Medical Institute

    Brooklyn, New York, 11214

  • Integrative Clinical Trials, LLC

    Brooklyn, New York, 11229

  • Meridien Research

    Brooksville, Florida, 34601

  • Valley Medical Research

    Centerville, Ohio, 45459

  • Brain and Spine Center

    Chandler, Arizona, 85226

  • Herbert Harris, MD, PhD, PA

    Chapel Hill, North Carolina, 27517

  • RH Johnson VA Medical Center

    Charleston, South Carolina, 29401

  • ANI Neurology PLLC dba Alzheimer's Memory Center

    Charlotte, North Carolina, 28270

  • Center for Emotional Fitness

    Cherry Hill, New Jersey, 08002

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212

  • Columbus Research & Wellness Institute, INC

    Columbus, Georgia, 31904

  • Texas Neurology, P.A.

    Dallas, Texas, 75214

  • Denver Neurological Research, LLC

    Denver, Colorado, 80210

  • Moonshine Research Center, Inc

    Doral, Florida, 33166

  • Science Connections, LLC

    Doral, Florida, 33166

  • Michigan State University

    East Lansing, Michigan, 48824

  • The Samuel & Alexia Bratton Memory Clinic

    Easton, Maryland, 21601

  • Health Initiatives Research

    Fayetteville, Arkansas, 72703

  • Behavioral Research Specialists, LLC

    Glendale, California, 91206

  • Finlay Medical Research Corp

    Greenacres City, Florida, 33467

  • Mir Neurology

    Hagerstown, Maryland, 21742

  • Indago Research & Health Center, Inc.

    Hialeah, Florida, 33012

  • New Life Medical Research Center, Inc.

    Hialeah, Florida, 33012

  • Reliable Clinical Research,LLC

    Hialeah, Florida, 33012

  • Research in Miami, Inc

    Hialeah, Florida, 33013

  • The Research Center, Inc

    Hialeah, Florida, 33013

  • Maxblue Institute

    Hialeah, Florida, 33018

  • Baylor College of Medicine

    Houston, Texas, 77030

  • Houston Methodist Neurological Institute

    Houston, Texas, 77030

  • Clinical Trial Network

    Houston, Texas, 77074

  • Josephson Wallack Munshower Neurology, PC

    Indianapolis, Indiana, 46256

  • Irvine Center for Clinical Research

    Irvine, California, 92614

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32256

  • Alzheimer's Research and Treatment Center

    Lake Worth, Florida, 33449

  • Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital

    Lakewood, Ohio, 44107

  • The Birches at Newton / Family Medical Associates

    Levittown, Pennsylvania, 19056

  • Premier Clinical Research Institute, Inc.

    Miami, Florida, 33122

  • Project 4 Research

    Miami, Florida, 33125

  • BioMed Research Institute

    Miami, Florida, 33126

  • CCM Clinical Research Group

    Miami, Florida, 33133

  • DADE Research Center, LLC

    Miami, Florida, 33135

  • AMB Research Center, Inc.

    Miami, Florida, 33144

  • United Health Research Corp

    Miami, Florida, 33144

  • Advance Medical Research Center

    Miami, Florida, 33165

  • Coral Research Clinic Corp

    Miami, Florida, 33175

  • P&S Reasearch

    Miami, Florida, 33175

  • The Neurology Research Group, LLC

    Miami, Florida, 33176

  • Kendall Research Institute

    Miami, Florida, 33183

  • Nuovida Research Center Corp.

    Miami, Florida, 33186

  • The NeuroCognitive Institute

    Mount Arlington, New Jersey, 07856

  • Collier Neurologic Specialists, LLC

    Naples, Florida, 34102

  • Eastside Comprehensive Medical Center, LLC

    New York, New York, 10128

  • Boston Center for Memory

    Newton, Massachusetts, 02459

  • AMAC Research Institute

    North Dartmouth, Massachusetts, 02747

  • Lazlo J. Mate, MD, PA

    North Palm Beach, Florida, 33408

  • Compass Research, LLC

    Orlando, Florida, 32806

  • IMIC Inc.

    Palmetto Bay, Florida, 33157

  • California Neurological Services

    Panorama City, California, 91402

  • Havana Research Institute

    Pasadena, California, 91105

  • University of West Florida

    Pensacola, Florida, 32514

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

  • Baptist Health Medical Group

    Richmond, Kentucky, 40475

  • Veteran Affairs Medical Center, Salem Virginia

    Salem, Virginia, 24153

  • Pharmaceuticals Research Associates, Inc.

    Salt Lake City, Utah, 84107

  • Texas Medical Research Associates, L.L.C.

    San Antonio, Texas, 78238

  • Pacific Research Network, Inc

    San Diego, California, 92103

  • Syrentis Clinical Research

    Santa Ana, California, 92705

  • BG Neurology

    Spartanburg, South Carolina, 29307

  • Viking Clinical Research

    Temecula, California, 92591

  • Territory Neurology & Research Institute

    Tucson, Arizona, 85704

  • IPC Research

    Waukesha, Wisconsin, 53188

  • Neurology Research Institute Palm Beach, LLC

    West Palm Beach, Florida, 33407

  • Burke Rehabilitation Hospital

    White Plains, New York, 10605

Other trials in United States

Canada4 sites
  • Dr. Alexander McIntyre Inc.

    Calgary, Alberta, N7L 1C1

  • The Medical Art Health Research Group

    Kelowna, Bristish Columbia

  • The Medical Art Health Research Group

    Penticton, Bristish Columbia

  • The Medical Art Health Research Group

    West Vancouver, Bristish Columbia

Other trials in Canada

About this study

Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.

Read the detailed description

Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.

This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment.

Approximately 470 participants will be enrolled at approximately 75 centers in North America.

Study medication will be administered orally twice-daily from Day 1 through Week 12 (Day 85). Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.

Being tested
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AVP-786-18Drug

    18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)

  • PlaceboDrug

    Administered as capsules.

  • AVP-786-28Drug

    28 mg of d6-DM and 4.9 mg of Q

  • AVP-786-42.63Drug

    42.63 mg of d6-DM and 4.9 mg of Q

Study groups in NCT02442778
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants were administered AVP-786 matching placebo capsules, orally, twice daily (BID) for up to 12 weeks.
Receives: Drug: Placebo
AVP-786-28ExperimentalParticipants were administered AVP-786-18 capsule, orally, once daily (QD) along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-18 capsules, orally, BID during Weeks 2, 3 and AVP-786-28 capsules, orally, BID during Weeks 4 to 12.
Receives: Drug: AVP-786-18; Drug: AVP-786-28
AVP-786-42.63ExperimentalParticipants were administered AVP-786-28 capsules, orally, QD along with AVP-786 matching placebo capsule, orally, QD during Week 1 followed by AVP-786-28 capsules, orally, BID during Weeks 2, 3, and AVP-786-42.63 capsules, orally, BID during Weeks 4 to 12.
Receives: Drug: AVP-786-28; Drug: AVP-786-42.63

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score

    The CMAI was used to assess the frequency of manifestations of agitated behaviors in elderly participants. It consists of 29 agitated items rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Negative change from baseline indicates improvement. Mixed Model Repeated Measures (MMRM) was used for the analysis.

    Measured: Baseline, Week 12

Secondary outcomes (17)
  1. Relative Change From Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score

    The mADCS-CGIC-Agitation is a modified version of the ADCS-CGIC containing additional questions related to agitation and an assessment of the Clinician's Impression of Change focused specifically on agitation. Participants are asked to rate their impression of change as: 1=Marked Improvement; 2=Moderate Improvement; 3=Minimal Improvement; 4=No Change; 5=Minimal Worsening; 6=Moderate Worsening; 7=Marked Worsening. Higher scores indicate worsening of agitation and positive change from baseline indicates worsening. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  2. Change From Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score

    The NPI is a retrospective caregiver-informant interview covering 12 neuropsychiatric symptom domains. The Agitation/Aggression domain is designed to collect information on the behavioral aspects of agitation/aggression in participants with probable AD and clinically meaningful agitation secondary to AD. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as:1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  3. Change From Baseline to Week 12 in the NPI Agitation/Aggression Caregiver Distress Score

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate caregiver distress. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as:1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as:1, mild; 2, moderate; 3, marked severe. The total caregiver distress score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12 with a higher score indicating worsening of symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  4. Change From Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate aberrant motor behavior. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, marked severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12 with a higher score indicating worsening of symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  5. Change From Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score

    The ZBI is a 22-item scale used to assess the impact of a participants' disabilities on the caregiver's life. It is designed to reflect the burden experienced by caregivers of dementia participants and can either be completed by the caregiver or administered as an interview. Each item of the scale is rated to reflect the burden using the 5-point scale: 0=Never; 1=Rarely; 2=Sometimes; 3=Quite Frequently; 4=Nearly Always. The ZBI is scored by summing the responses of the individual questions and ranges from 0 to 88. Higher scores indicate greater caregiver distress. Negative change from baseline indicates less distress. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  6. Change From Baseline to Week 12 in the NPI Irritability/Lability Domain Score

    The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains, including the irritability/lability domain score. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as:1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as:1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Negative change from baseline indicates improvement in symptoms. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  7. Change From Baseline to Week 12 in the NPI Total Score

    NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, night time behaviors, as well as appetite/eating. Total domain score= frequency x severity and thus ranges from 1 to 12. NPI domain is rated by caregiver for symptom frequency and severity. Frequency is rated as:1=occasionally, 2=often, 3= frequently, and 4=very frequently. Severity is rated as:1=mild,2=moderate,3=severe. Frequency and severity rating scales has defined anchor points to enhance reliability of caregiver responses. Caregiver distress is rated for each positive neuropsychiatric symptom using following anchored scores. It is rated as 0=not at all,1=minimal,2=mild,3=moderate,4=severe,5=very severe. Individual Item scores are added to yield a possible total score of 0 to 144. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  8. Change From Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score

    The CGIS-Agitation is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1=normal, not at all ill participants; 7=among the most extremely ill participants) and is assessed for severity of agitation. A value of 0 is given to participants who are not assessed. Higher scores indicate poor health of participants. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  9. Change From Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating

    The ADCS-CGIC rating scale provides a reliable means to assess change from a Baseline level of global function within the time frame of the trial. ADCS-CGIC-Overall focuses on the clinician's observations of change in the participant's cognitive, functional, and behavioral performance. The ADCS-CGIC-Overall responses (1-7) are rated as: 1 = marked improvement, 2 = moderate improvement, 3 = minimal improvement, 4 = no change, 5 = minimal worsening, 6 = moderate worsening, or 7 = marked worsening. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  10. Change From Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score

    The PGIC is a 7-point (1-7) scale used to assess treatment response: 1 = very much improved, = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Higher scores indicate less response to treatment. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  11. Change From Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score

    The DEMQOL scale is used to evaluate health-related QOL in participants with dementia and their caregivers. There are 2 versions of the DEMQOL: a 28-item version (rated by the participant); and a 31-item version (DEMQOL-proxy, rated by the caregiver). Both versions are recommended for evaluating participants (and their caregivers) with mild to moderate dementia. The DEMQOL total score ranges from 28 to 112. The DEMQOL-proxy is used for participants with severe dementia; the total score ranges from 31 to 124. For both versions, higher scores indicate greater QOL. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  12. Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score

    The CSDD scale is used to assess signs/symptoms of major depression in participants with dementia. CSDD has 19 items, and each item is rated for severity on the following scale of 0 to 2 (0 =absent, 1= mild/intermittent 2=severe). CSDD score is calculated by summing non-missing scores from each item score. The scale ranges from 0 (no depression) to 38 (maximum depression). Scores above 10 indicate a probable major depression, above 18 indicate a definite major depression, and below 6 as a rule are associated with the absence of significant depressive symptoms. Higher score indicated maximum depression. MMRM was used for the analysis.

    Measured: Baseline, Week 12

  13. Number of Participants With the Change From Baseline in the General Medical Health Rating (GMHR) Score at Week 12

    The GMHR is a global clinical rating for medical health, designed to quantify in a single number (1 to 4) the severity of general comorbidity in a participant with dementia. The ratings are: 1 = poor; 2 = fair; 3 = good; 4 = excellent to very good. MMRM was used for the analysis.

    Measured: Week 12

  14. Change From Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score

    The ADAS is designed to evaluate the cognitive and non-cognitive behavioral dysfunction characteristics of participants with AD. The cognitive subscale (ADAS-cog) consists of 11 subsets related to memory, praxis, and language. ADAS-cog scores range from 0 to 70. Higher scores indicate greater cognitive impairment. Negative change from baseline indicates less cognitive impairment. MMRM method was used for analysis.

    Measured: Baseline, Week 12

  15. Resource Utilization in Dementia (RUD) Score: Number of Hours Per Day the Caregiver Spent Assisting the Participant

    The RUD evaluates dementia participants' utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. Information on hours per day the caregiver spent assisting participant were reported in this outcome measure, using the following questions:

    Q1= On a typical care day during the last 30 days, how much time per day did you assist the participant with tasks such as toilet visits, eating, dressing, grooming, walking and bathing? Q2= On a typical care day during the last 30 days, how much time per day did you assist the participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters? Q3= On a typical care day during the last 30 days, how much time per day did you spend supervising (that is, preventing dangerous events) the participant?

    Measured: Week 12

  16. Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant

    The RUD evaluates dementia participants' utilization of formal and informal healthcare resources, including hospitalizations, doctor visits, living assistance, and time spent by nonprofessional caregivers. Information on days the caregiver spent assisting participant were reported in this outcome measure, using the following questions:

    Q1= During the last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking and bathing) services to the participant? Q2= During the last 30 days, how many days did you spend providing these (shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters) services to the participant? Q3= During the last 30 days, how many days did you spend providing these services (supervising) to the participant?

    Measured: Week 12

  17. Resource Utilization in Dementia (RUD) Score: Number of Visits to Hospital, Emergency, and Healthcare Professional

    The RUD evaluates dementia participants' utilization of formal and informal healthcare resources, including hospitalizations, doctor visits, living assistance, and time spent by nonprofessional caregivers. Information on the number of hospital visits, emergency visits and visits to healthcare professional were reported in this outcome measure using the following questions:

    Q1= During the last 30 days, how many times did the participant receive care in a hospital emergency room (for less than 24 hours)? Q2= During the last 30 days, how many times did the caregiver receive care in a hospital emergency room (for less than 24 hours)? Q3= During the last 30 days total number of visits by participant to a health care professional? Q4= During the last 30 days, how many times (number of visits for each) the participant visited any other health care professional?

    Measured: Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2015 (estimated)
  2. Study start11 Nov 2015
  3. Primary completion14 Aug 2019
  4. Study completion9 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
522 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02442778
Sponsor's protocol ID
15-AVP-786-302
Status last verified
Aug 2022
First submitted
11 May 2015
Last updated
9 Sep 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researcher sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing AVP-786-18, AVP-786-28 and AVP-786-42.63 in people with Agitation in Participants With Dementia of the Alzheimer's Type, run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 83 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 83 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in